OssDsign AB (OSSD) AI Stock Analysis

• Market Cap: kr1.37B
• Dividend Yield: N/A
• Average Volume (3M): 297.02K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.14
• Revenue Growth: 38.43%
• EPS Growth: 57.76%
• Country: SE
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.05
• Shares Outstanding: 110,597,374
• 10 Day Avg. Volume: 325,245
• 30 Day Avg. Volume: 297,022
• PEG Ratio: 0.29
• Price to Book (P/B): 4.57
• Price to Sales (P/S): 7.31
• P/FCF Ratio: -15.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: kr11.00 ▼(-11.00% Downside)

OssDsign AB's overall stock score is primarily influenced by its financial performance and technical analysis. The company's strong revenue growth and gross margin improvements are overshadowed by persistent losses and negative cash flows. Technical indicators suggest a bearish trend, and valuation metrics reflect the company's unprofitability. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for OssDsign's products and effective market penetration, supporting long-term business expansion.

Gross Margin Improvement

High gross margins suggest effective cost management and pricing power, enhancing profitability potential as the company scales.

Solid Equity Base

A strong equity base provides financial stability and flexibility, enabling OssDsign to invest in growth opportunities and withstand economic fluctuations.

Negative Factors

Unprofitability

Continued unprofitability can hinder long-term sustainability, requiring strategic adjustments to achieve break-even and profitability.

Negative Cash Flows

Negative cash flows can strain liquidity and limit the company's ability to fund operations and growth without external financing.

Negative Return on Equity

Negative return on equity indicates inefficiency in generating returns from shareholders' investments, potentially affecting investor confidence.

OssDsign AB Business Overview & Revenue Model

Company Description

OssDsign AB (OSSD) is a pioneering medical technology company specializing in the development and commercialization of innovative biomaterials for cranial and orthopedic applications. The company focuses on creating advanced solutions that enhance patient outcomes through the use of its proprietary products, which are designed to promote bone regeneration and healing. OssDsign's core offerings include custom-made implants that utilize a unique 3D printing technology to tailor solutions to individual patient needs, primarily targeting neurosurgery and orthopedic surgery sectors.

How the Company Makes Money

OssDsign AB generates revenue through the sale of its proprietary biomaterial implants and related products in the medical field. The company primarily earns income from hospitals and surgical centers that purchase its custom implants for use in surgical procedures. Key revenue streams include direct sales of their products, which are often billed to healthcare providers or insurance companies, as well as potential royalties from partnerships with larger medical device companies that may license OssDsign's technology. Additionally, the company may benefit from collaborations with research institutions and participation in clinical trials, which can enhance its market presence and drive further sales.

OssDsign AB Financial Statement Overview

Summary

OssDsign AB is experiencing strong revenue growth and improved gross margins, indicating potential for future profitability. However, persistent losses and negative cash flows are significant challenges. The company benefits from a strong equity base and low leverage, providing some financial stability.

Income Statement

OssDsign AB has shown significant revenue growth over the years, with a CAGR of approximately 35% from 2019 to 2024. The company has improved its gross profit margin, reaching 95.38% in 2024, indicating strong pricing power or cost control. However, the company remains unprofitable, with a net profit margin of -37.07% in 2024, and EBIT and EBITDA margins also remain negative. The trend of narrowing losses suggests potential for future profitability if the trajectory continues.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 69.61% in 2024, indicating a solid capital structure. The debt-to-equity ratio is low at 0.009, showcasing low financial leverage. Despite this, the consistent negative net income impacts return on equity, which remains negative. The company has a sizable cash position, which provides financial flexibility.

Cash Flow

OssDsign AB's cash flows remain challenging, with substantial negative operating cash flow and free cash flow in 2024. The operating cash flow to net income ratio is negative, indicating cash outflows exceed losses. However, the free cash flow improved slightly compared to 2023, suggesting some operational improvements. Continued negative cash flows could pose liquidity risks if not addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	176.48M	133.94M	112.16M	56.98M	31.73M	24.87M
Gross Profit	170.12M	127.75M	83.64M	45.13M	20.84M	16.00M
EBITDA	-37.43M	-45.31M	-122.02M	-89.41M	-79.97M	-80.64M
Net Income	-41.76M	-49.66M	-130.49M	-99.39M	-93.92M	-84.59M
Balance Sheet
Total Assets	430.71M	307.42M	356.39M	339.50M	343.99M	246.65M
Cash, Cash Equivalents and Short-Term Investments	210.86M	100.86M	165.94M	124.65M	151.37M	49.40M
Total Debt	1.64M	1.97M	3.15M	13.60M	14.13M	17.24M
Total Liabilities	83.43M	93.36M	105.26M	91.39M	81.26M	134.58M
Stockholders Equity	347.27M	214.06M	251.13M	248.11M	262.72M	112.07M
Cash Flow
Free Cash Flow	-57.88M	-63.04M	-94.03M	-89.36M	-89.84M	-81.59M
Operating Cash Flow	-54.18M	-62.38M	-93.91M	-89.23M	-89.78M	-79.10M
Investing Cash Flow	-5.16M	-657.00K	-124.00K	-129.00K	-51.85M	-17.67M
Financing Cash Flow	161.74M	-2.46M	135.40M	61.84M	243.43M	33.18M

OssDsign AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:OSSD, the sentiment is Negative. The current price of 12.36 is above the 20-day moving average (MA) of 11.23, above the 50-day MA of 11.98, and below the 200-day MA of 13.37, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 52.51 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:OSSD.

OssDsign AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	66 Neutral	kr1.07B	46.45	6.93%	―	-5.80%	-65.99%
PAX	52 Neutral	kr1.28B	204.20	1.41%	―	21.71%	-80.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSSD	50 Neutral	kr1.37B	-28.90	―	―	38.43%	57.76%
SEDANA	48 Neutral	kr1.05B	-25.17	-4.42%	―	13.48%	28.98%
BACTI.B	46 Neutral	kr571.22M	-28.74	-6.81%	―	-8.10%	62.08%
SEZI	43 Neutral	kr822.23M	-6.08	-36.55%	―	62.24%	21.16%

OssDsign AB Corporate Events

OssDsign’s Spine Registry Study: A Potential Game-Changer in Bone Graft Substitutes

The OssDsign® Spine Registry Study, officially titled ‘PROSPECTIVE OBSERVATIONAL SPINE FUSION REGISTRY FOR OssDsign® BONE GRAFT SUBSTITUTES IN REAL WORLD CLINICAL PRACTICE,’ aims to evaluate the clinical outcomes and real-world application of OssDsign® AB’s bone graft substitutes in spine fusion surgeries. This study is significant as it seeks to provide valuable insights into the effectiveness of these substitutes in treating conditions like Degenerative Disc Disease and Spinal Stenosis.